Suppliers / “Reliance Life Sciences

“Reliance Life Sciences

India Updated 9 July 2026

“Reliance Life Sciences is an API manufacturer based in India. It holds 13 active US drug master files across a filed portfolio of 15 molecules. Its filings concentrate with DIGEMAPS (DO), INHRR (VE) and ARCSA (EC). Its GMP standing is certified by EMA, EAEU_EEC and INVIMA (CO), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 15 April 2022 as NAI. Customs aggregates show $6.3M of exports covering 107 molecules to 21 destinations in 2025.

13
active US DMFs
0
valid CEPs
6
registered plants 1 with an FDA FEI number
162
filings across 13 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 15 April 2022 NAI US FDA
  • 22 November 2019 VAI US FDA
  • 16 October 2018 VAI US FDA
  • 25 January 2018 NAI US FDA
  • 13 December 2017 VAI US FDA
  • 14 August 2015 VAI US FDA
  • 23 August 2013 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Navi Mumbai, United Arab Emirates Not on file
Maharashtra, United Arab Emirates Not on file
Mumbai 24239 Mh 2011 Ptc 130654, Colombia Not on file
Maharashtra, Colombia Not on file
Navi Mumbai, India 3009510975
Thane, India Not on file

What they file, and where

Molecule Regulators Docs
Bortezomib SFDA (Saudi Arabia), US FDA 2
Erlotinib SFDA (Saudi Arabia), US FDA 2
Lenalidomide SFDA (Saudi Arabia), US FDA 2
Azacitidine US FDA 1
Capecitabine US FDA 1
Dasatinib US FDA 1
Decitabine US FDA 1
Imatinib US FDA 1
Lanreotide US FDA 1
Pemetrexed US FDA 1
Show all 15 molecules on file
Pemetrexed Disodium SFDA (Saudi Arabia) 1
Sorafenib US FDA 1
Sunitinib US FDA 1
Sunitinib Malate SFDA (Saudi Arabia) 1
Temozolomide US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 54 None
INHRR (VE) 32 None
ARCSA (EC) 23 None
CDSCO (India) 18 None
MINSA (CR) 6 None
EDE (AE) 6 None
EMA None 5
EAEU_EEC None 3
INVIMA (CO) None 2
UZPHARM (UZ) None 2

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $23.9M 41
2025 Not reported $6.3M 21

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. “Reliance Life Sciences comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 15 April 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts